Phase I Study of Duvelisib Study for Cytokine Release Syndrome Prophylaxis in Patients Receiving Chimeric Antigen Receptor T Cell Treatment for Non-Hodgkin Lymphoma

CAR T-cell therapy toxicities, including CRS and immune cell-associated neurotoxicity syndrome (ICANS), can be significant and effective prophylactic strategies are needed. Duvelisib is an oral inhibitor of phosphoinositide 3-kinases (PI3K)- γ/δ and is FDA-approved therapy for CLL/NHL with an established safety profile. Pre-clinical work from our group has demonstrated that PI3K inhibition may prevent CRS.We are conducting a Phase I, 3 + 3 dose escalation and two-arm dose expansion, trial of duvelisib for CRS prophylaxis in patien ts (pts) undergoing standard-of-care (SoC) CAR T-cell therapy for non-Hodgkin lymphoma (NHL) (NCT05044039).

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Michael Slade, Michael P. Rettig, Zachary D Crees, Neha Mehta-Shah, Nancy L. Bartlett, Todd A Fehniger, Amanda Cashen, Dr. Iskra Pusic, Geoffrey L. Uy, Peter Westervelt, John F. DiPersio, Armin Ghobadi Tags: 146 Source Type: research